Haem 9 - Bone marrow transplantation Flashcards

1
Q

What is the principle of cyclical chemotherapy?

A

• Normal cells recover more efficiently than malignant cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

o Myeloablation vs

o Non-myeloablation

A

o Myeloablation = Threshold of radiation that you can give to the patient above which the haematopoietic system will not recover and unless supported the patient will inevitably die

o Non-myeloablation = There is also a threshold where you get temporary ablation of the haematopoietic system but if you can support the patient through it (abx, blood transfusions, platelet transfusions), haematopoiesis will recover

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How are the HLA encoded?

A

Encoded by MHC on Chr 6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Chance of an HLA match within the family

Each sibling has a x% chance of being HLA-identical with the patient

A

Each sibling has a 35% chance of being HLA-identical with the patient

Given n siblings the probability that at least one with be HLA identical is given by the formula 1 – 3^n/4^n

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How is autologous transplantation carried out

A
  • GCSF (granulocyte colony stimulating factor) given  BM proliferation  release of stem cells (CD34+ cells) into peripheral blood  collect + freeze stem cells
  • Patient given high-dose chemoradiotherapy is given to eradicate the bone marrow  thaw + reinfuse the stem cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Allogenic SCT indication + how is it carried out

A
  • Used when patient’s disease is unlikely to be eradicated from the bone marrow by standard chemotherapy e.g. Thalassaemia, sickle cell disease, congenital immune deficiencies
  • Give them high dose chemoradiotherapy to ablate the bone marrow (malignant and normal cells)  infuse haemopoietic system/BM from a healthy donor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Principles of transplantation `

A

o Identify disease unlikely to respond to standard treatment

o Treat patient to remission

o Identify donor  collect stem cells

o Give patient myeloablative therapy

o Infuse stem cells

o Continue immunosuppression and support patient through period of cytopaenia (neutropenia, thrombocytopenia, anaemia) until the donor cells engraft and start producing cells of their own

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Marker of stem cells

A

CD34+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Which organs does acute chronic gvhd affect and whtn do they present?

A
acute
<100 days/ within first 3 months of transplant
skin - rash itchy dry
GIT - D
Liver - jaundice hepatitis
chronic
>100 days/ after first 3 months of transplant 
skin - rash
liver - jaundice hepatitis
mucosal membranes  - dry mouth, ulcers
eyes - dry
joints - arthritis
lungs - SOB
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Cell responsible for gvhd?

Mx?

A

Cell - donor lymphocytes

mx - CSA (cyclosporin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Why do we get acute gvhd?

A
  • High dose chemoradiotherapy  dividing cells are killed
  • Dying cells release cytokines + chemokines, IL, IFN, TNF
  • Infusion of stem cell product contains donor lymphocytes

• Lymphocytes get stimulated by
o All of the products released from dying cells
o Peptides from dead cells presented on HLA molecules

• Then T cells begin to stimulate the B cells

cytokines also activate APCs which then present the antigens to the donor lymphocytes  immune reaction against the host tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Why are donor lymphocytes important and why dont we get rid of them to prevent gvhd?

A

the donor lymphocytes are important in the prevention of relapse

Graft vs leukaemia effect = Donor lymphocytes throughout the patient’s bodies are capable of recognising any emerging leukemic cells as foreign and killing it before it can cause relapse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How is gvhd staged and graded?

A

o Depends on how bad the skin/liver/GIT are affected

grade = add the stages of the organs together

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

RF for acute gvhd

A

o Degree of HLA disparity

o Recipient age

o Conditioning regimen
 Worse if you use irradiation in the preparative regimens

o R/D (recipient/donor) gender combination
 Worse for M patients with F donors
 Why? Because may F donors will have had male children  sensitised against proteins that are produced by the Y antigen

o Stem cell source
 You get more lymphocytes in peripheral blood than in the bone marrow
 Therefore more GvHD with peripheral blood

o Disease phase
 The more advanced the disease, the worse the GvHD

o Viral infections
 Viral infection activate T cells which can aggravate GvHD and vice versa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Treatment of acute GvHD

A

o Corticosteroids

o Calcineurin inhibitors – Cyclosporin A, tacrolimus, sirolimus

o Mycophenolate mofetil

o Monoclonal antibodies against T cells, IL, TNF
 Can be used to suppress T cell activation

o Photopheresis
 Patient sensitised to UV light by the administration of a drug
 Then put on a pheresis machine
 When the cells come out and are exposed to UV radiation  destroys lymphocytes

o Total lymphoid irradiation

o Mesenchymal stromal cells
 Have an anti-inflammatory role

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

GVHD prophylaxis

A

o Methotrexate
 Effective in prophylaxis
 Not effective in the treatment

o CS

o Calcineurin inhibitors – cyclosporin A, tacrolimus, sirolimus

o CsA plus MTX

o T-cell depletion from donor product before we infuse it

o Post-transplant cyclophosphamide
 To turn of the T-cell response that is caused by the cytokine storm

17
Q

RF for chronic gvhd

A

o Prior acute GvHD
 Strongest RF

o Increased degree of HLA disparity

o Male recipient : Female donor

o Stem cell source (PB>BM>UCB)

o T-cell replete
 Remove T cells from the product before it goes into the patient

o Older donor age

o Use of DLI (donor lymphocyte infusion)

18
Q

Infection in the first 30 days post transplant

type
reason
commonest
most fatal

A

Bacterial infections –> Most common when the patient is neutropenic + there is barrier breakdow

o The most frequently isolated organisms are gram +ve e.g. staph epidermidis (e.g. Central vascular access becomes colonised)

o Most deaths from sepsis are due to gram -ve organisms e.g. e.coli, pseudomonas aeruginosa (Chemoradiotherapy causes a lot of mucosal damage (e.g. damaged bowel wall allows gut bacteria to spread))

19
Q

Which T cells recover first after translant?

A

NK + CD8 first

B cells and CD4 recover slowly later on

20
Q

viral infection post transplant

acute
chronic

A

acute - HSV first, then CMV (CMV within the first 30 days)

Chronic - EBV first, then VZV

HSV –> CMV –> EBV –> VZV

21
Q

Define sepsis

A

• = temperature >38 sustained for 1 hour or single fever >39 in a patient with neutrophils <1.0 x 10^9/L

22
Q

CMV disease manifestations

A

Pneumonitis

Retinitis

Gastritis - colitis

Encephalitis

23
Q

CMV disease prevention

A

o 2x weekly quantitative monitoring of peripheral blood viraemia to day 100 (PCR)

o Ganciclovir/valganciclovir – oral and IV preparations

o Minimum of 2/52 treatment with clear evidence of reduction in viral load

24
Q

myeloma/lymphoma transplant

A

o Treat the patient with normal chemotherapy  get the BM as free as possible of malignant cells

o At that point, collect + freeze stem cells

o Give dose a bigger dose of chemoradiotherapy to eradicate the bone marrow

o Then give them back the stem cells

o Allogeneic transplant is very dangerous and risky in these patients so this is why you go for autologous transplantation

25
Q

Autografting rather than allografting is the preferred option for treating myeloma because

A

transplant related mortality after allografting is unacceptably high in most patients with myeloma

26
Q

• Affecting the outcomes of transplants = EBMT risk score

A

• Affecting the outcomes of transplants = EBMT risk score:
o Age
<20=0, 20-40=1, >40=2

o Disease phase
Early=0, int=1, late=2

o Gender of R/D
Female into male = 1

o Donor
Sibling = 0, VUD (volunteer unrelated donor) = 1

o Time to BMT
<1 yr = 0, >1 yr = 1